home / stock / lctx / lctx quote
Last: | $1.105 |
---|---|
Change Percent: | -2.21% |
Open: | $1.12 |
Close: | $1.13 |
High: | $1.12 |
Low: | $1.07 |
Volume: | 182,714 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.105 | $1.12 | $1.13 | $1.12 | $1.07 | 182,714 | 05-02-2024 |
$1.13 | $1.11 | $1.13 | $1.13 | $1.09 | 562,065 | 05-01-2024 |
$1.09 | $1.12 | $1.09 | $1.15 | $1.08 | 766,968 | 04-30-2024 |
$1.12 | $1.14 | $1.12 | $1.17 | $1.12 | 428,510 | 04-29-2024 |
$1.14 | $1.11 | $1.14 | $1.14 | $1.11 | 313,340 | 04-26-2024 |
$1.11 | $1.1 | $1.11 | $1.14 | $1.1 | 359,695 | 04-25-2024 |
$1.1 | $1.15 | $1.1 | $1.15 | $1.1 | 747,332 | 04-24-2024 |
$1.14 | $1.13 | $1.14 | $1.1856 | $1.13 | 333,219 | 04-23-2024 |
$1.14 | $1.14 | $1.14 | $1.17 | $1.12 | 429,952 | 04-22-2024 |
$1.15 | $1.22 | $1.15 | $1.23 | $1.12 | 1,099,086 | 04-19-2024 |
$1.2 | $1.3 | $1.2 | $1.3 | $1.18 | 1,040,693 | 04-18-2024 |
$1.29 | $1.16 | $1.29 | $1.32 | $1.16 | 2,315,885 | 04-17-2024 |
$1.15 | $1.24 | $1.15 | $1.27 | $1.15 | 766,210 | 04-16-2024 |
$1.25 | $1.31 | $1.25 | $1.325 | $1.22 | 678,976 | 04-15-2024 |
$1.3 | $1.41 | $1.3 | $1.43 | $1.29 | 1,045,589 | 04-12-2024 |
$1.41 | $1.38 | $1.41 | $1.45 | $1.33 | 857,091 | 04-11-2024 |
$1.35 | $1.35 | $1.35 | $1.41 | $1.33 | 543,031 | 04-10-2024 |
$1.4 | $1.47 | $1.4 | $1.47 | $1.335 | 715,033 | 04-09-2024 |
$1.47 | $1.42 | $1.47 | $1.47 | $1.405 | 935,963 | 04-08-2024 |
$1.4 | $1.46 | $1.4 | $1.47 | $1.38 | 1,205,930 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
BioTime Inc. Company Name:
LCTX Stock Symbol:
NYSE Market:
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development...